In his weekly clinical update Dr. Griffin discusses prevalence and clinical outcomes of respiratory syncytial virus versus influenza virus in adults hospitalized with acute respiratory Illness, reconsideration of antinucleocapsid IgG antibody as a marker of SARS-CoV-2 infection postvaccination for mild COVID-19 patients, assessment of COVID-19 as the underlying cause of death among children and young people aged 0 to 19 years in the US, information for persons who are immunocompromised regarding prevention and treatment of SARS-CoV-2 Infection in the context of currently circulating Omicron sublineages, association of culturable-virus detection and household transmission of SARS-CoV-2, effectiveness of bivalent boosters against severe Omicron infection, Covid vaccines and playing the long game, efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19, and severe fatigue and persistent symptoms at three months following SARS-CoV-2 Infections during the pre-Delta, Delta, and Omicron time periods.
In his weekly clinical update Dr. Griffin discusses co-detections of other respiratory viruses among children hospitalized with COVID-19, preprint review should form part of PhD programs and postdoc training, early and increased Influenza activity among children, COVID-19 vaccines versus pediatric hospitalization, SARS-CoV-2 variant-related abnormalities detected by prenatal MRI, protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the Omicron variant and severe disease, protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease, persistent COVID-19 Symptoms at 6 months after onset and the role of vaccination before or after SARS-COV-2 infection, effect of Dexamethasone use on viral clearance among patients with COVID-19, and the impact of vaccination on post-acute sequelae of SARS CoV-2 infection in patients with rheumatic diseases.
In his weekly clinical update Dr. Griffin discusses China reporting almost 60,000 Covid-related deaths after abrupt shift in policy, detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination, effect of Fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19, hyperimmune globulin for severely immunocompromised patients hospitalized with COVID-19, long COVID outcomes at one year after mild SARS-CoV-2 infection, long COVID: major findings, mechanisms and recommendations, a systematic review of trials currently investigating therapeutic modalities for post-acute COVID-19 syndrome and registered on World Health Organization international clinical trials platform, and the effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome.
In his weekly clinical update Dr. Griffin discusses poliovirus returns to New York wastewater, COVID-19 is more widespread in animals than we thought, increasing ventilation reduces SARS-CoV-2 airborne transmission in schools, the use of carbon dioxide monitoring to assess ventilation at a national infectious diseases conference, effectiveness of the bivalent mRNA vaccine in preventing severe COVID-19 outcomes, 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection, and long COVID outcomes at one year after mild SARS-CoV-2 infection.
In his weekly clinical update Dr. Griffin discusses the infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave, virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants, antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants, comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans, time to negative PCR conversion among high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated by Sotrovimab or Nirmatrelvir, COVID drug Paxlovid was hailed as a game-changer, what happened?, the Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice, SARS-CoV-2 infection and persistence in the human body and brain at autopsy, long-term cardiovascular outcomes of COVID-19, and how heart-disease risk soars after COVID — even with a mild case.
In his weekly clinical update Dr. Griffin discusses modelling the adjustment of COVID-19 response and exit from dynamic zero-COVID in China, canine real-time detection of SARS-CoV-2 infections in the context of a mass screening event, two masks can be worse than one: N95 respirator failure caused by an overlying face mask, airflow patterns in double-occupancy patient rooms may contribute to roommate-to-roommate transmission of severe SARS-CoV-2, clinical validation of a novel T-Cell receptor sequencing assay for identification of recent or prior SARS-CoV-2 infection, antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera, regardless of the infecting variant, VV116 versus Nirmatrelvir–Ritonavir for oral treatment of Covid-19, Nirmatrelvir plus Ritonavir for early COVID-19 in a U.S. health system, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, higher dose corticosteroids in hospitalized COVID-19 patients with hypoxia but not requiring ventilatory support, FDA approves Roche’s Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults, structural brain changes in post-acute COVID-19 patients with persistent olfactory dysfunction, persistent post–COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium, epidemiology of long COVID in US adults, persistent symptoms and sequelae after SARS-CoV-2 infection not requiring hospitalization, and outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up.
In his weekly clinical update Dr. Griffin discusses how immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection, prevalence of SARS-CoV-2 and influenza coinfection and clinical characteristics among children and adolescents aged <18 years who were hospitalized or died with Influenza, WHO estimates of excess mortality associated with the COVID-19 pandemic, reconsideration of anti-nucleocapsid IgG antibody as a marker of SARS-CoV-2 infection post-vaccination for mild COVID-19 patients, impact of SARS-CoV-2 variants on inpatient clinical outcome, clinical features and burden of post-acute sequelae of SARS-CoV-2 infection in children and adolescents, similar SARS-CoV-2 Ct value distributions in anterior nares versus nasopharyngeal samples from symptomatic children during Delta and Omicron surges, early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19, effect of Nirmatrelvir/Ritonavir vs Placebo on COVID-19─related hospitalizations and other medical visits, COVID-19 Convalescent Plasma outpatient therapy to prevent outpatient hospitalization, bacterial co-infection and empirical antibiotic therapy in patients with COVID-19, association of time to surgery after COVID-19 infection with risk of postoperative cardiovascular morbidity, demonstration of stable clusters of symptoms in long COVID, and how longitudinal analysis of t cells in COVID-19 survivors with post-acute sequelae of COVID-19 reveals associations between individual symptoms and inflammatory indexes.
In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Afghanistan, reduced risk for Mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons, reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters, authorized updated (Bivalent) COVID-19 vaccines for children down to 6 months of age, low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster, efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB, incidence of viral rebound after treatment with Nirmatrelvir-Ritonavir and Molnupiravir, and the effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post–COVID-19 conditions.
In his weekly clinical update Dr. Griffin discusses Mpox (formerly monkeypox) in women: epidemiological features and clinical characteristics of mpox cases in Spain, April to November 2022, triage of patients with Ebola virus disease, SARS-CoV-2 serology and self-reported infection among adults, serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals, sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants, effect of wearing glasses on risk of infection with SARS-CoV-2 in the community, and data-driven identification of post-acute SARS-CoV-2 infection subphenotypes.
In his weekly clinical update Dr. Griffin discusses effectiveness of influenza vaccination of pregnant women for prevention of maternal and early infant Influenza-associated hospitalizations in South Africa, a multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes, single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic induce durable B cell memory responses comparable to replicating smallpox vaccines, whether the risk of still and preterm birth is affected by the timing of symptomatic SARS-CoV-2 infection during pregnancy, medical masks versus N95 respirators for preventing COVID-19 among health care workers, alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants, real-world evidence of novel treatments for COVID-19 on mortality: a nationwide comparative cohort study of hospitalized patients in the 1st, 2nd, 3rdand 4th wave in the Netherlands, and effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19.